ALT
SHORT CANDIDATEMeanRevComposite
26.90
Technical
26.10
Fundamental
27.10
Rank
—
Price
2.88
Hurst
0.35
As of
Aug 14, 2026
Daily
Altimmune, Inc.
HealthcareBiotechnologyAltimmune is a biopharmaceutical firm developing treatments for severe hepatic conditions. Its primary candidate, pemvidutide, is a dual-action GLP-1/glucagon receptor agonist currently undergoing Phase 3 testing for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-related liver disease. Founded in 1997, the company is based in Gaithersburg, Maryland.
Market cap
$396.8M
P/E (trailing)
—
P/E (forward)
-3.05
PEG ratio
32.62
Dividend yield
0.00%
Beta
0.06
52w range
1.99 – 6.44
Return on equity
-28.88%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 2.04 (-49.6%) · range 2.04–6.18
Cycle position
0/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 85 · STRONG SETUP · exit proximity 0
Conviction
46/ 100 · maturity 0%
Buildup.3312
EMA entry setup.4285
Fundamentals.2527
Volume profile
POC
3.00
Price vs POC
-32.1%
Overhead supply
99%
Runway
+42.7%
Value area 2.74–3.30 · 99% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +5.14% | +9.97% | mature |
| 40d | -28.30% | +9.97% | mature |